Most Read Articles
03 Apr 2019
The sodium‐glucose‐cotransporter‐2 inhibitor empagliflozin yields beneficial effects on weight anthropometric parameters and body composition—including weight, body mass index, waist and hip circumference, and total body fat—that are greater than those achieved with metformin in overweight and obese women with polycystic ovary syndrome (PCOS), a study has shown.
Stephen Padilla, 03 Apr 2019
The risk of miscarriage is lowest at age 27 years but increases with older age and by up to four times after three consecutive previous miscarriages, according to a Norway study. This risk is also associated with earlier pregnancy complications, including stillbirth, preterm delivery and gestational diabetes.
Pearl Toh, 08 May 2019
Continuous chemotherapy confers better survival and quality of life than intermittent scheduling in patients with advanced breast cancer, according to the Stop&Go study presented at EBCC 2019.

Norepinephrine more potent than phenylephrine for hypotension during C-section

4 days ago

Norepinephrine is a more potent choice than phenylephrine for postspinal hypotension during elective caesarean section, a recent study has found.

The study included 100 patients with postspinal hypotension, who were treated with a predetermined dose of either phenylephrine or norepinephrine. Resolution of hypotension within 1 minute of administration was considered a success. The corresponding 95 percent (ED95) and 50 percent (ED50) effective doses for norepinephrine and phenylephrine, as well as the potency ratio, were calculated.

There were 50 participants each in the norepinephrine (mean age, 25.9±3.6 years) and phenylephrine (mean age, 25.7±3.7 years) groups. Probit analysis revealed that ED95 and ED50 values were 43.1 and 33.2 µg for phenylephrine, respectively, and 3.7 and 3.2 µg for norepinephrine, respectively.

The resulting potency ratio was 11.3:1, suggesting that norepinephrine is at least 11 times more potent than phenylephrine.

There were also more patients in the phenylephrine than norepinephrine group who developed further hypotension episodes after the delivery of the baby and required rescue phenylephrine. However, the difference was not statistically significant (42 percent vs 38 percent; p=0.838).

Neonatal Apgar scores at 1 and 5 minutes (p=1.00) and birth weights (2.7±0.4 vs 2.6±0.4 kg; p=0.214) were also statistically comparable between the phenylephrine and norepinephrine groups.

In terms of safety, 10 percent in the phenylephrine group complained of nausea, as opposed to only 6 percent in the norepinephrine group. On the other hand, 6 percent and 2 percent reported vomiting in the respective treatment arms.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Apr 2019
The sodium‐glucose‐cotransporter‐2 inhibitor empagliflozin yields beneficial effects on weight anthropometric parameters and body composition—including weight, body mass index, waist and hip circumference, and total body fat—that are greater than those achieved with metformin in overweight and obese women with polycystic ovary syndrome (PCOS), a study has shown.
Stephen Padilla, 03 Apr 2019
The risk of miscarriage is lowest at age 27 years but increases with older age and by up to four times after three consecutive previous miscarriages, according to a Norway study. This risk is also associated with earlier pregnancy complications, including stillbirth, preterm delivery and gestational diabetes.
Pearl Toh, 08 May 2019
Continuous chemotherapy confers better survival and quality of life than intermittent scheduling in patients with advanced breast cancer, according to the Stop&Go study presented at EBCC 2019.